The global metabolomics market is estimated to reach USD 2.39 Billion by 2021, at a CAGR of 14.6% during the forecast period.
The growing acceptance of metabolomics for personalized medicine, increasing pharmaceutical and biotech R&D expenditure, and continuous technological advancements are some of the factors driving market growth. New range of enhanced technologies for accuracy and precision in metabolomics research and growth in emerging markets due to increasing investments presents significant growth opportunities for players in the market. However, issues related to data examination and processing and high-cost tools and instruments and their maintenance are the major restraining factors for this market.
In this report, the global metabolomics market has been studied at the regional and country levels. In 2015, North America represented the largest regional market, followed by Europe. North America will continue to dominate the market during the forecast period, the Asia-Pacific region is expected to register the highest growth. The growth of this regional segment is driven by the significant economic development in emerging markets, metabolomic technologies playing an integral role in the modern pharmaceutical and healthcare industries, and rising focus of key market players in this region.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Biocrates Life Sciences AG
- Bruker Corporation
- Danaher Corporation
- Human Metabolome Technologies, Inc.
- Leco Corporation
- Metabolon, Inc.
- Shimadzu Corporation
- Thermo Fisher Scientific Inc.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Industry Insights
7 Technology Investment Potential
8 Global Metabolomics Market, By Product and Service
9 Global Metabolomics Market, By Application
10 Global Metabolomics Market, By Indication
11 Global Metabolomics Market, By Region
12 Competitive Landscape
13 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/dcc33x/metabolomics